Showing 15 posts of 15 posts found.

Bayer image

Profits fall at Bayer but new drugs see growth

May 1, 2015
Sales and Marketing Bayer, Eliquis, Eylea, Renegeron, Xarelto, apixaban

Bayer’s pharmaceutical revenues have continued their upward trajectory in the first quarter of 2015 thanks to new products, although this …

Eliquis image

Anti-blood clotting drug Eliquis gets NICE nod

March 6, 2015
Sales and Marketing BMS, DVT, Eliquis, NICE, Pfizer, Pradaxa, apixaban, clotting

Bristol-Myers Squibb and Pfizer’s Eliquis for preventing blood clots has been shown the green light to treat venous thromboembolism (VTE), …

Pfizer image

Pfizer posts fourth-quarter revenue decline

January 28, 2015
Sales and Marketing Eliquis, Lipitor, Lyrica (pregablin), Pfizer, Read, Xeljanz, apixaban, financials, pneumococcal vaccine Prevnar, q4, tofacitinib citrate

Pfizer posted a 3% decline in revenue in the last quarter of 2014, the company’s latest financial results show. The …

Boehringer Ingelheim

Pradaxa and Eliquis gain trial boost over warfarin

August 31, 2011
Sales and Marketing Eliquis, Pradaxa, Xarelto, apixaban

A pair of new blood thinners are superior to warfarin when it comes to reducing the risk of stroke in …

Pfizer and BMS to give Eliquis a rolling launch in Europe

May 24, 2011
Sales and Marketing Eliquis, Pfizer, apixaban, atrial fibrillation

Pfizer and Bristol-Myers Squibb are gearing up to give their new oral anticoagulant Eliquis a rolling launch in Europe, starting …

Pfizer and BMS’ blood thinner Eliquis approved in Europe

May 23, 2011
Sales and Marketing BMS, Eliquis, Pfizer, apixaban

Pfizer and Bristol-Myers Squibb’s eagerly anticipated blood thinner Eliquis has gained European approval. A twice-daily oral Factor Xa inhibitor, Eliquis …

Companies join forces to promote AF awareness

February 16, 2011
Medical Communications, Sales and Marketing AF, Multaq, Pradaxa, apixaban, atrial fibrillation

Boehringer Ingelheim and Sanofi-Aventis are to co-sponsor the World Heart Federation’s global atrial fibrillation (AF) education campaign. AF AWARE was …

VTE trial boost for Pfizer and BMS’ apixaban

December 31, 2010
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Pfizer, VTE, apixaban, enoxaparin, venous thromboembolism

Pfizer and Bristol-Myers Squibb’s oral anticoagulant apixaban has shown benefits over a standard injectable treatment for venous thromboembolism in a …

Apixaban trial for ACS abandoned

October 20, 2010
Sales and Marketing ACS, BMS, Pfizer, apixaban

  Pfizer and Bristol-Myers Squibb have halted a trial of their heart drug apixaban after signs of increased risk of …

Pradaxa, Xarelto and apixaban vie for attention

September 6, 2010
Research and Development, Sales and Marketing Pradaxa, Xarelto, apixaban, atrial fibrilation

New data has intensified the competition between three rival would-be cardiology blockbusters. Boehringer Ingelheim’s Pradaxa (dabigatran) and Bayer’s Xarelto (rivaroxaban) …

Novel anticoagulants set to lead atrial fibrillation market

July 9, 2010
Sales and Marketing Brinavess, Multaq, Pradaxa, Xarelto, apixaban, atrial fibrilation

Novel anticoagulants set to capture the atrial fibrillation market by 2019, according to a new report. Analysts Decision Resources say …

Early halt for successful apixaban trial

June 14, 2010
Research and Development apixaban, atrial fibrilation

Pfizer and Bristol-Myers Squibb’s atrial fibrillation treatment apixaban has performed so well in a phase III trial that it has …

Study boost for atrial fibrillation drugs

March 17, 2010
Research and Development Pradaxa, VTE, Xarelto, apixaban, betrixaban

Two rival drugs have both shown benefits over warfarin in patients with atrial fibrillation, according to new research. Boehringer Ingelheim’s …

Blood clot

Phase III success for apixaban

March 5, 2010
Research and Development BMS, Pfizer, VTE, apixaban

Pfizer and Bristol-Myers Squibb’s apixaban has shown promising results in a late-stage head-to-head trial with Sanofi-Aventis’ Lovenox. The oral anti-coagulant …


BMS and Pfizer will file apixaban in Europe next year

December 8, 2009
Sales and Marketing BMS, Pfiizer, Pfizer, VTE, apixaban

Bristol-Myers Squibb and Pfizer are to submit their new anti-clotting drug for European approval in the first half of next …

Latest content